Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE4
400 participants
INTERVENTIONAL
2026-01-31
2032-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sitagliptin
Sitagliptin 100 mg given 2 hours prior to the oral glucose tolerance test
Oral Glucose Tolerance Test
Three hour glucose tolerance test
Placebo
Placebo given 2 hours prior to the oral glucose tolerance test
Oral Glucose Tolerance Test
Three hour glucose tolerance test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral Glucose Tolerance Test
Three hour glucose tolerance test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Members of Old Order Amish community in Lancaster, PA
Exclusion Criteria
* Diabetes: HbA1c \> 6.5% or fasting plasma glucose \>126 mg/dL
* Estimated glomerular filtration rates (eGFR) \<60 mL/min/1.73 m2
* Anemia: hematocrit \< 35%
* Thyroid status: TSH\<0.4 or TSH\>5.5
* ALT or AST in excess of 2X upper limit of normal
* Drugs that in the physician's judgment would alter response to sitagliptin
* Significant health issues that in the physician's judgment could increase the risk for participants.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Maryland, Baltimore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amber Beitelshees
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amber L Beitelshees, PharmD, MPH
Role: PRINCIPAL_INVESTIGATOR
University of Maryland, Baltimore
Simeon I Taylor, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Maryland, Baltimore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Maryland Amish Research Clinic
Lancaster, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HP-00111892
Identifier Type: -
Identifier Source: org_study_id